Mississauga, ON -- (SBWIRE) -- 09/15/2014 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled “Clinical Trial Shows Vascazen by Pivotal Therapeutics Helps Correct Omega 3 Deficiency in Cardiovascular Disease Patients.”
Companies mentioned in this article include Pivotal Therapeutics (OTCQX:PVTTF)(CSE:PVO).
Article Excerpt:
With obesity rates at high levels, it’s not surprising that so many people are told to cut down on fats. The guidance comes with an asterisk, though, as not all fats are bad. In fact, there are fats that are essential to diets to promote healthy brain development and function. Appropriately, these are called Essential Fatty Acids, or EFAs. Omega-3 and Omega-6 are two of the critical EFAs. Without getting to granular as to composition, understand that both come in short-chain and long-chain types, with the long-chain form being the most desirable to maintain homeostatic health. In short, this means that getting Omega-6 from margarine or fried food (short-chain) is not as healthy as getting it from meat or eggs (long-chain). In the big picture, imbalances in EFAs or deficiencies are believed to contribute to brain disorders, such as depression, Attention Deficit Hyperactivity Disorder and even Alzheimer’s. Further, Omega-3 fatty acids, which are a type of unsaturated fatty acid, are thought to reduce inflammation in the body, inflammation that can damage blood vessels and lead to heart disease.
Pivotal Therapeutics (OTCQX:PVTTF)(CSE:PVO), is a specialty pharmaceutical company focused on Omega-3 therapies for cardiovascular disease and general health. The company, which has offices in Woodbridge, Ontario, Canada and Boca Raton, Florida, has commercialized two products: prescription-only medical food Vascazen® sold in the United States as a treatment for Omega-3 deficiency in patients with cardiovascular disease (CVD); and Omazen®, a natural health, ultra pure Omega-3 product sold in Canada.
The full version of this article can be found at:
http://www.allpennystocks.com/aps_ca/special-reports/449/clinical-trial-shows-vascazen-by-pivotal-therapeutics-helps-correct-omega-3-deficiency-in-cardiovascular-disease-patients.htm
About AllPennyStocks.com:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.